Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Recent news :
May 2026 – Affilogic CEO Olivier Kitten is presenting at Nasal Formulation and Delivery Summit in Boston, USA : He will present how our Nanofitins® are intranasally delivered, with an example on anti-viral Nanofitins®, and the impact on mucosal immunity.
May 2026 – Mathieu Cinier is presenting at PEGS Boston, USA : Come and meet Mathieu at the event, showcasing our latest results on our ODC Program, in which we use Nanofitins for fast and deep tumor penetration and delivery of cytotoxic payloads.
Around the world
BIO Japan 2026
Affilogic is attending at next Bio Japan taking place in Yokohama, Japan
Oct 7- 8, 2026
BioHorizon 2026
Affilogic is presenting at next BioHorizon taking place in Laval, Quebec
Oct 7- 9, 2026
Discovery On Target 2026
Affilogic is presenting at next Discovery On Target taking place in Boston, USA
Sep 28- Oct 01, 2026
Nanofitins
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read More
Our Programs
Affilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read More
NanoVector
Affilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More